Leodolter S, Sainz H, Moll-Schüler I, Mach R
Gynäkologisch-Geburtshilfliche Abteilung, Lainz/Wien.
Gynakol Geburtshilfliche Rundsch. 1992;32(4):201-4. doi: 10.1159/000271889.
In an open-label, multicentric randomized trial the efficacy and tolerability of Estraderm TTS, a 17 beta-estradiol, and Premarin, consisting of conjugated estrogens, were compared in the treatment of the climacteric syndrome. 84 patients with manifest menopausal complaints were randomized into two groups of 42 women each. The duration of treatment was 11 weeks or 3 cycles, each with 3 weeks of estrogen treatment followed by a therapy-free week. Therapeutic efficacy was assessed with a questionnaire recording frequency and intensity of hot flushes and of sweating episodes during the night, changes in psychic well-being, frequency of micturition and dryness of the vagina. Systemic and local tolerability was also evaluated. Both substances proved almost equivalent in the treatment of menopausal complaints, although Estraderm TTS was markedly superior in suppressing vasomotor symptoms.
在一项开放标签、多中心随机试验中,比较了17β - 雌二醇的Estraderm TTS贴剂和含有结合雌激素的倍美力在治疗更年期综合征方面的疗效和耐受性。84名有明显更年期症状的患者被随机分为两组,每组42名女性。治疗持续时间为11周或3个周期,每个周期包括3周的雌激素治疗,随后是1周的无治疗期。通过问卷调查评估治疗效果,问卷记录潮热和夜间出汗发作的频率和强度、心理健康状况的变化、排尿频率和阴道干燥情况。还评估了全身和局部耐受性。两种药物在治疗更年期症状方面几乎等效,尽管Estraderm TTS贴剂在抑制血管舒缩症状方面明显更优。